Innovation in heart rhythm management

We are developing innovative therapies to transform the way atrial fibrillation is treated, from hospital to home.

Our focus

Innovative therapies designed to restore normal heart rhythm — from hospital to home

Hospital-based innovation

We are developing rapid, effective therapies for safe cardioversion during inpatient and outpatient hospital care.

At-home empowerment

Next-generation solutions to let patients self-administer treatment in the comfort of home.

Driven by science

We are guided by clinical insight, rigorous research, and a commitment to improving patient outcomes.

Our team

Experts in heart rhythm care

United by a mission to improve lives, our multidisciplinary team develops innovative therapies for atrial fibrillation.

Dr. Myles Greenberg

CEO

Dr. Luiz Belardinelli

CMO

Carol Manchester, CPA

CFO

Carlos Schuler, PhD

CTO

Narsi Rangachari, M.Pharm.

CBO

Leo Santana

Controller

Ramakrishna Nekkanti, MBA

FP&A

Dawn Parsell, PhD

Head Regulatory

Sarah McNulty

Regulatory Ops

Kate Ecklund, MPH

Head Clnical Ops

Julie Rogers

Clinical Manager

Jean Maupas, MD

Data Management

Miguel Guzman, PhD

Head CMC

Board of Directors

Guiding our vision with experience and leadership

Michael Hurley, M.D.

Daniel Welch

Louis Lange, M.D., Ph.D

Johan Christenson, M.D., Ph.D.

Investors

Contact

Connect with us to learn more

We’d love to hear from you — whether you’re a patient, clinician, partner, or investor, our team is ready to connect.